期刊
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
卷 18, 期 9, 页码 3845-3858出版社
IVYSPRING INT PUBL
DOI: 10.7150/ijbs.70958
关键词
NSCLC; tumor microenvironment; VEGF; VEGFR pathway; immunotherapy; clinical trials
资金
- Science and Technology Research Fund of Sichuan Administration of Traditional Chinese Medicine [2021MS528]
- Science and Technology Strategic Cooperation Programs of Luzhou Municipal People's Government and Southwest Medical University [2019LZXNYDJ25, 2019LZXNYDJ45]
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide, with poor prognosis. Vascular endothelial growth factor (VEGF) plays a crucial role in tumor angiogenesis and immunomodulation in NSCLC. Current research focuses on understanding the functions of VEGF in NSCLC and its interaction with the tumor microenvironment, as well as exploring novel treatment approaches targeting VEGF/VEGFR and immunotherapy.
Non-small cell lung cancer (NSCLC) is the leading cause of death by cancer worldwide. Despite developments in therapeutic approaches for the past few decades, the 5-year survival rate of patients with NSCLC remains low. NSCLC tumor is a complex, heterogeneous microenvironment, comprising are a major mediator to induce tumor microvasculature and are associated with the progression, recurrence, and metastasis of NSCLC. Current treatment medicines targeting VEGF/VEGF receptor (VEGFR) pathway, including neutralizing antibodies to VEGF or VEGFR and receptor tyrosine kinase inhibitors, have shown good treatment efficacy in patients with NSCLC. VEGF is not only an important angiogenic factor but also an immunomodulator of tumor microenvironment (TME). VEGFs can suppress antigen presentation, stimulate activity of regulatory T (Treg) cells, and tumor-associated macrophages, which in turn promote an immune suppressive microenvironment in NSCLC. The present review focuses on the angiogenic and non-angiogenic functions of VEGF in NSCLC, especially the interaction between VEGF and the cellular components of the TME. Additionally, we discuss recent preclinical and clinical studies to explore VEGF/VEGFR-targeted compounds and immunotherapy as novel approaches targeting the TME for the treatment of NSCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据